IRIS
SFRAMELI, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.320
NA - Nord America 3.042
AS - Asia 2.139
SA - Sud America 768
AF - Africa 61
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 2
Totale 10.340
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.964
RU - Federazione Russa 2.320
SG - Singapore 824
BR - Brasile 667
CN - Cina 661
IE - Irlanda 521
PL - Polonia 303
SE - Svezia 301
IT - Italia 269
HK - Hong Kong 216
DE - Germania 154
FR - Francia 151
VN - Vietnam 136
GB - Regno Unito 101
FI - Finlandia 92
IN - India 86
MX - Messico 44
AR - Argentina 34
BD - Bangladesh 29
TR - Turchia 28
CA - Canada 22
ZA - Sudafrica 20
IQ - Iraq 18
AT - Austria 17
BE - Belgio 16
EC - Ecuador 16
NL - Olanda 16
JP - Giappone 15
UZ - Uzbekistan 15
VE - Venezuela 15
ID - Indonesia 14
MA - Marocco 13
PK - Pakistan 13
UA - Ucraina 13
CO - Colombia 10
JO - Giordania 9
AE - Emirati Arabi Uniti 8
CZ - Repubblica Ceca 8
KE - Kenya 8
PE - Perù 8
SA - Arabia Saudita 8
CI - Costa d'Avorio 7
ES - Italia 7
EU - Europa 7
LT - Lituania 7
NP - Nepal 7
PH - Filippine 7
MY - Malesia 6
OM - Oman 5
PY - Paraguay 5
TN - Tunisia 5
AL - Albania 4
BO - Bolivia 4
CL - Cile 4
IL - Israele 4
KZ - Kazakistan 4
UY - Uruguay 4
AZ - Azerbaigian 3
BH - Bahrain 3
CR - Costa Rica 3
EG - Egitto 3
HU - Ungheria 3
JM - Giamaica 3
KG - Kirghizistan 3
NI - Nicaragua 3
PA - Panama 3
RS - Serbia 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
CY - Cipro 2
DZ - Algeria 2
GE - Georgia 2
HR - Croazia 2
KR - Corea 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
TJ - Tagikistan 2
BW - Botswana 1
CH - Svizzera 1
EE - Estonia 1
ET - Etiopia 1
GY - Guiana 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
NO - Norvegia 1
PS - Palestinian Territory 1
RO - Romania 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TW - Taiwan 1
UG - Uganda 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 10.340
Salva come PNG Salva come JPEG
Città #
Moscow 634
Ashburn 547
Dublin 520
Singapore 453
Chandler 416
Warsaw 295
Dallas 293
Beijing 272
Hong Kong 216
Nyköping 195
San Jose 123
The Dalles 121
Princeton 103
Lauterbourg 75
Ann Arbor 73
Los Angeles 73
Jacksonville 72
Medford 72
Munich 68
Messina 59
Cambridge 56
Des Moines 46
Ho Chi Minh City 43
Pune 42
São Paulo 42
Bremen 37
Lancaster 35
Tianjin 35
Boardman 34
Buffalo 34
Turku 34
New York 31
Redondo Beach 31
Dearborn 30
Houston 27
Hanoi 25
Rome 25
Shenyang 25
San Mateo 24
Frankfurt am Main 22
Rio de Janeiro 22
Belo Horizonte 21
Jinan 21
Orem 19
Wilmington 19
Council Bluffs 18
Nanjing 17
Brussels 16
Guangzhou 16
Brasília 15
Dong Ket 15
Hebei 15
Porto Alegre 15
Tashkent 15
Tokyo 15
Chennai 14
Poplar 13
Shanghai 13
Atlanta 12
Curitiba 12
Mexico City 12
Ningbo 12
Hangzhou 11
Johannesburg 11
Seattle 11
Amsterdam 10
Amman 9
Ankara 9
Baghdad 9
Campinas 9
Guadalupe 9
Haikou 9
Jakarta 9
Santa Clara 9
Stockholm 9
Taizhou 9
Vienna 9
Chicago 8
Falls Church 8
Nuremberg 8
Phoenix 8
Toronto 8
Zhengzhou 8
Abidjan 7
Brooklyn 7
Denver 7
Helsinki 7
Manchester 7
Montreal 7
Nairobi 7
Palo Del Colle 7
São Bernardo do Campo 7
Boston 6
Cagliari 6
Catania 6
Changsha 6
Charlotte 6
Goiânia 6
Guarulhos 6
Guayaquil 6
Totale 6.006
Salva come PNG Salva come JPEG
Nome #
Clinical and molecular characterization of patients affected by congenital muscular dystrophies using next generation sequencing strategies 274
A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript “single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1” written by pechmann and colleagues” 221
Which are the factors influencing NIV adaptation and tolerance in ALS patients? 198
Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study 197
Modulation of neuronal nitric oxide synthase and apoptosis by the isoflavone genistein in Mdx mice 193
Effect of exercise on telomere length and telomere proteins expression in mdx mice 186
Autonomic nervous system involvement in spinal muscular atrophy. 184
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 184
Nusinersen versus sham control in later-onset spinal muscular atrophy 182
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test 173
Intrathecal administration of Nusinersen in type 1 SMA: successful psychological program in a single Italian center 173
Pilot study of flavocoxid in ambulant DMD patients. 167
Pilot study of serial casting in muscular dystrophy patients. 165
Neuropsychological patter in centronuclear myopathy due to DNM2 gene mutations. 165
Pilot study of serial casting of ankles in muscular dystrophy patients. 164
Modulation of neural nitric oxide synthase by the isoflavone genistein promotes muscle regeneration in mdx mice 163
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 162
An observational study of functional abilities in infants, children, and adults with type 1 SMA 159
Predictors of adaptation to non-invasive ventilation in amyotrophic lateral sclerosis 158
Emotional burden and coping strategies in amyotrophic lateral sclerosis caregivers: The role of metacognitions 154
Predictors of adaptation to non-invasive ventilation in neuromuscular disorders. 152
Psycological status and emotional burden in amyotrophic lateral sclerosis caregivers: the role of metacognitive processes. 152
The 24-month PUL changes and steroids correlation. 151
Pilot study of flavocoxid in ambulant DMD patients. 149
Outcome measures in Duchenne muscular dystrophy: validation of the Pediatric Quality of Life InventoryTM Neuromuscular Module in the Italian population and correlation with other functional assessments. 149
Pilot study of flavocoxid in ambulant DMD patients. 149
Activation of NF-kappaB pathway in Duchenne muscular dystrophy: relation to age 149
Psychosocial impact of sport activity in neuromuscular disorders 148
Severe rhabdomyolysis in a patient with “Heat Stroke” 146
Burden, social network and professional support in the families of patients with muscular dystrophies: results from the GUP10002 study. 143
Impaired rotational mechanics and strain revealing subclinical left ventricular dysfunction in children with Duchenne muscular dystrophy: a skeckle tracking study. 143
Burden, professional support, and social network in families of children and young adults with muscular dystrophies 143
The 6-min walk test as a new outcome measure in Amyotrophic lateral sclerosis 143
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 142
First report of a family with a DMD out of frame exon 2 deletion associated with asymptomatic phenotypes. 139
Development of an academic disease registry for spinal muscular atrophy 139
Clinical variability in spinal muscular atrophy type III 139
Teriparatide (rhPTH 1-34) in Duchenne Muscular Dystrophy related osteoporosis: a case report. 138
Clinical and genetic spectrum in a large cohort of patients with a genetic diagnosis of Congenital Muscular Dystrophies in the UK and differences with the Italian population 135
Teriparatide (rhPTH 1-34) in Duchenne Muscular Dystrophy related osteoporosis: a case report 134
First report of a family with a DMD out of frame exon 2 deletion associated with asymptomatic phenotypes. 134
Selective short-term verbal memory involvement in two siblings carrying centronuclear myopathy due to DNM2 gene mutations 133
Integrated care of muscular dystrophies in Italy. Part 1. Pharmacological treatment and rehabilitative interventions 131
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 131
Impaired rotational mechanics and strain revealing subclinical left ventricular dysfunction in children with neuromuscolar disorders: a speckle tracking study 128
study of flavocoxid in ambulant DMD patients. 127
Integrated care of muscular dystrophies in Italy. Part 2. Psychological treatments, social and welfare support, and financial costs 125
Clinical and genetic spectrum in a large cohort of patients with a genetic diagnosis of Congenital Muscular Dystrophies: Analysis of the UK diagnostic service 2001-2013. 122
Telomere shortening and telomere associated proteins in exercised wild type and mdx mice. 121
Pilot study of flavocoxid in ambulant DMD patients. 118
The 6 minute walk test and performance of upper limb in ambulant duchenne muscular dystrophy boys 115
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 114
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 113
MYH7-related myopathies: Clinical, histopathological and imaging findings in a cohort of Italian patients 113
Congenital myastenic syndromes due a novel GFPT1 mutation: a new Italian case 110
Psychological and practical difficulties among parents and healthy siblings of children with Duchenne vs. Becker muscular dystrophy: an Italian comparative study 110
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 107
Pilot study of flavocoxid in ambulant DMD patients. 99
The first report of a patient carrying an out-of-frame exon2 deletion in the dystrophin gene and showing a very unusual phenotype. 98
Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study 98
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 93
The respiratory symptom check-list for patients with myotonic dystrophies: preliminary results. 88
Stato dell'arte sulle terapie della Distrofia muscolare di Duchenne. 85
Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function 84
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 83
Old measures and new scores in spinal muscular atrophy patients 83
Neuropsychiatric comorbidities in Duchenne Muscular Dystrophy. 83
The first report of a patient carrying an out-of-frame exon2 deletion in the dystrophin gene and showing a very unusual phenotype. 81
Molecular analysis of SMARD1 patient-derived cells demonstrates that nonsense-mediated mRNA decay is impaired 75
The families of children with muscular dystrophies: burden, social network and professional support. 73
“I have got something positive out of this situation”: Psychological benefits of caregiving in relatives of young people with muscular dystrophy 71
Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. 70
Sleep disorders in spinal muscular atrophy 69
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 66
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 65
The genetic spectrum of a large cohort of putative CMD. 64
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 61
Outcome measures in Duchenne muscular dystrophy: validation of the Pediatric Quality of Life Inventory TM neuromuscular Module in the Italian population and correlation with other functional assessments. 58
Screening for early symptoms of respiratory involvement in myotonic dystrophy type 1 using the Respicheck questionnaire 57
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 55
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 54
null 27
null 22
Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function 21
null 20
null 20
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 19
null 18
null 15
Totale 10.532
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.088
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.088
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202166 0 0 0 0 0 0 0 0 0 36 9 21
2021/2022491 3 43 5 34 24 4 44 18 8 54 39 215
2022/20231.432 98 146 69 105 129 122 10 70 638 9 29 7
2023/2024367 17 61 18 52 22 96 31 15 0 6 5 44
2024/20251.776 39 35 38 109 57 51 65 369 400 130 182 301
2025/20265.104 270 328 353 371 452 1.076 635 689 707 223 0 0
Totale 10.532